Investor Presentation & Financial Highlights
February 2020
NASDAQ:ZYXI
Forward Looking Statements
- Certain statements in this release are"forward-looking" or projections and as such are subject to numerous risks and uncertainties. The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2019 as well as Forms 10-Q,8-K and 8-K/A, press releases and the Company's website.
NASDAQ: ZYXI | 2 |
Zynex Medical Overview
Background
- NASDAQ:ZYXI (Listed 2019)
- Listed on OTCQB from2004-2018
- Founded By Thomas Sandgaard-CEO and Chairman
- Medical Device Manufacturer - 23 Years
- HQ - Englewood, Colorado
- More than 400,000 patients treated
Business Units
•ZYNEX MEDICAL (ZMI)
Non-invasive electrotherapy pain management devices "TENS" (90% of historical revenue)
•Rx required, insurance billed
•>75% GPM, >60% recurring revenue (consumable supplies and rentals)
•ZYNEX NEURODIAGNOSTICS (ZND)
EEG, EMG diagnostics B:B products (<2% of historical revenue)
NeuroMove Stroke Rehab product
•ZYNEX MONITORING SOLUTIONS (ZMS)
Fully developed, non-invasive blood volume monitor (Zero revenue)
NASDAQ: ZYXI | 3 |
Zynex Financial Snapshot
Financial Highlights
- 14 consecutive profitable quarters
- Executed $3.8 million in Stock Buybacks in2017-2019
- One-TimeSpecial Dividend of $0.07 per share in Q4-18.
- Q1-2020Guidance - Revenue $14.0 to $14.5 million, Adjusted EBITDA $2.3 to $2.8 million
- 2020 Full year guidance - Revenue $75.0 to $80.0 million, Adjusted EBITDA$15.0-$18.0 million
- Adding sales reps at15-20 per month
Selected Financials Quarters Ended December 31, 2019 vs 2018
- Net revenue↑52% to $14.2M from $9.3M
- GM's 80%
- Net income↑12% to $2.9M from $2.6M
- A-EBITDA↑30% to $4.1M from $3.1M
- Orders↑129%
- Working capital $17.4M vs $7.3M at 12/31/18
- Cash $14.0M
- Nolong-term debt
NASDAQ: ZYXI | 4 |
Pain & Rehabilitation
NexWave | $950 million | ||||
Augments healing, alleviates | Electrotherapy | ||||
swelling through increased blood | industry | ||||
circulation, and reduces both | |||||
worldwide | |||||
acute/chronic pain through the use | |||||
of electrical currents | |||||
InWave | Incontinence | $5 Billion | |||
Delivers a nonsurgical, drug-free | industry | ||||
therapy that offers a conservative | Treatment | ||||
worldwide | |||||
treatment to manage incontinence | |||||
and is of relatively low cost to | |||||
patients. | |||||
NeuroMove | $100 million | ||||
Augment healing, as well as | Stroke Rehab | industry | |||
assist in recovery for stroke, | |||||
Spinal Cord Injuries and | worldwide | ||||
Traumatic Brain Injury, retrains | |||||
muscles, increases range of | |||||
motion | |||||
- All devices above are FDA approved.
NASDAQ: ZYXI | 5 |
NexWave: Electrotherapy for Pain Management
- Indications: Pain relief, augments healing, alleviates swelling through increased blood circulation, musclere-education, prevention of muscle disuse atrophy, relaxation of muscle spasms.
- NexWave Electrotherapy eliminates or reduces use of Opioids.
- Only 23% of patients with chronic pain found opioids effective
- 51% of people feel that they have no control over their pain
- 84% of patients were able to reduce medication use.
- Nearly half reduced medication by 50%
- Patients decreased the cost of medication by 50%
- Effectivepost-orthopedic surgery.
- Requires a prescription & reimbursed by health insurance
- Average reimbursement including supplies ≈ $1,500
- $500 million industry worldwide
- Competitors shut down by Office of Inspector General (OIG)
- 1.5 Billion + worldwide suffering from chronic pain
- Over 75% gross profit margin
- Greater than 70% of revenue from supplies
NASDAQ: ZYXI | 6 |
NexWave: Electrotherapy for Pain Management
3 Modalities in 1 Device
- IFC (Interferential Current)
- 40x stronger than TENS
- Reaches deeper, stimulating motor nerves to release endorphins or enkephalins which results in pain relief that can last for hours (Endorphin Release Theory)
- 3-4treatments per day
- Frequency: Ranges from 4000 - 4128 Hz
- TENS (Transcutaneous Electrical Nerve Stimulation)
- Supplemental to IFC treatments
- Used for breakthrough pain
- More superficial as compared to IFC, stimulating sensory nerves to provide immediate onset of relief (Gate Control Theory)
- Can be used during activities
- Frequency: Ranges from 1 - 125 Hz, Pulse Width: 120 - 300 μs
- NMES (Neuromuscular Electrical Stimulation)
- Reduces muscle relaxant use
- Breaks up muscle spasms
- Strengthens atrophied muscles
- Increases ROM (Range of Motion) & blood circulation
- Improves overall ADLs (Activities of Daily Living)
- Frequency: Fixed at 35 Hz, Pulse Width: 480 μs
NASDAQ: ZYXI | 7 |
NexWave: Electrotherapy for Pain Management
Most Common Types of Chronic Pain
- 27% Back Pain, 15% Neck Pain
NASDAQ: ZYXI | 8 |
Blood Volume Monitor
Used in
•$3 Billion
CM-1500
operating and
industry
recovery rooms
to detect blood
worldwide.
loss and internal
bleeding
- Zynex Monitoring Solutions - CM1500
- US Patent obtained October 2018.
- European Patent obtained February 2020
- FDA 510(k) clearance received in February 2020
- CE marking (European Market) in progress.
- The CM1500 is capable of monitoring a patient's fluid levels, including blood loss, during surgery and in recovery
- Product fully developed
NASDAQ: ZYXI | 9 |
Long-Term Objectives
- Increase national footprint with additional direct sales representatives
- Grow recurring revenue streams
- Generate consistent net earnings and positive free cash flow
- Focus on driving value thru organic growth and strategic acquisitions
10
NASDAQ: ZYXI
Executive Team
THOMAS SANDGAARD - FOUNDER, CHAIRMAN AND CHIEF EXECUTIVE
Thomas Sandgaard has been the Chairman of the Board, President and Chief Executive Officer of Zynex, Inc. since founding the company in 1996. He has previously held management positions with companies such as ITT, Siemens, GN Danavox, Dataco and Philips. He is experienced in international sales and distribution, technology transfers, mergers and marketing management in industrails and medical equipment industries. Mr. Sandgaard has a bachelor's degree in electronics engineering from University of Southern Denmark and an MBA from Copenhagen Business School.
JOSEPH PAPANDREA - CHIEF OPERATING OFFICER
Joseph Papandrea joined the company in 2019 and leads operations including billing, patient support, sales and device production. Mr. Papandrea previously worked as Vice President of Operations at Arrow Electronics. He has extensive global operational experience to achieve scale and transformation in electronics, energy, healthcare and medical technology industries. Prior to joining Arrow electronics Mr. Papandrea worked in Australia, Singapore, Germany, the UK, Chile and the USA in a variety of senior leadership roles.
Mr. Papandrea holds a Bachelor of Commerce from the University of Western Sydney in Australia.
DAN MOORHEAD - CHIEF FINANCIAL OFFICER
Dan Moorhead joined the company in June 2017 as CFO. Mr. Moorhead has over 20 years of experience in a variety of finance roles serving both public and private companies. For the last 10 years, he worked at Evolving Systems, Inc. (a Nasdaq listed company), most recently as Chief Financial Officer after having served as Vice President of Finance & Administration and Corporate Controller. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.
CHRIS BROWN - VICE PRESIDENT OF SALES & MARKETING
Chris Brown is the Vice President of sales and marketing and is responsible for Zynex Medical's sales organization throughout the United States. Mr. Brown has extensive experience in sales and marketing in the healthcare industry. Previously, he held Vice President positions with Safeop Surgical, Nuvasive/Impulse Monitoring, Intelistaff Healthcare and Steris Corp/AMSCO. Chris holds a Bachelor's Degree in Business Administration from Indiana University of Pennsylvania.
1996
1999
2001
2004
2008
2010
2011
2015
2015
2018
2019
2020
Company Milestones
- Founded by Thomas Sandgaard
- FDA clearance on first ZynexE-Stim device
- Shifted from wholesale to direct sales to physicians and patients
- Reverse merger into a public entity
- Received European CE mark on key products
- Established NeuroDiagnostics (EEG/Sleep) and Monitoring (blood volume) subsidiaries
- Commenced clinical evaluations for Blood Volume Monitor device
- TENS business begins to grow. EMPI (largest competitor) exits TENS market
- Filed FDA 510K application for CM1500 monitoring device
- U.S. Patent obtained on CM1500 monitoring device
- Listed on The Nasdaq Capital Market - February 12th
- FDA clearance on Blood Volume Monitor - February 21st
NASDAQ: ZYXI | 12 |
- Q4-19revenue ↑52% vs Q4-18
- Q4-19device revenue ↑117% vs Q4-18
NASDAQ: ZYXI | 13 |
- Q4-2019↑30% vs Q4-18
• Q4-2019 14thstraight profitable quarter
NASDAQ: ZYXI | 14 |
Stock Information
Key Stats | |
Ticker | NASDAQ: ZYXI |
Shares Outstanding | 32.8 M |
Public Float | 16.3M |
Insider Ownership | 51% |
Avg. Daily Volume (50 days) | 322,830 |
52 Week Range | $4.25 - $14.10 |
Year End | December 31st |
NASDAQ: ZYXI | 15 |
Stock Chart
NASDAQ: ZYXI | 16 |
Contact Information
Amato and Partners, LLC | Zynex, Inc. |
Investor Relations Counsel | 9555 Maroon Circle |
100 Park Avenue, 16thFloor | Englewood, CO 80112 |
New York, NY 10017 | Telephone: (800) 495-6670 |
admin@amatoandpartners.com | www.zynex.com |
Zynex, Inc.
Dan Moorhead
Chief Financial Officer
Telephone: (303) 867-3904
dmoorhead@zynex.com
NASDAQ: ZYXI | 17 |
Attachments
- Original document
- Permalink
Disclaimer
Zynex Inc. published this content on 28 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 February 2020 15:51:21 UTC